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Cancer Center researcher John Groopman, Ph.D., is studying how environmental toxins 
cause cancer. (Photo by Bradford F. Herzog) 
Research on Aflatoxin Yields New Test, Possible 
Protective Measures Against a Potent Carcinc^en 
Not all cancer research at the Hubert H. 
Humphrey Cancer Research Center takes 
place entirely in the laboratory. An ex-
ample is the recent work on the agricul-
tural contaminant, aflatoxin, by Cancer 
Center researcher John Groopman, 
Ph.D., which has taken him from farms 
in the United States to remote villages in 
China and Africa. 
A principal focus of Dr. Groopman's 
studies has been on the role of aflatoxin 
in the development of liver cancer. 
Aflatoxin is a potent carcinogen 
produced by certain molds that common-
ly contaminate a variety of agricultural 
crops. Although the incidence of liver 
/ ' ^ cancer is relatively low in this country, it 
IS practically endemic in some areas of 
the world, perhaps because so much of 
the grain consumed in those regions is 
heavily contaminated with aflatoxin. 
Aflatoxin poisoning of livestock, grain 
and milk supplies has a deleterious effect 
on local economies everywhere. 
Approximately 100 aflatoxins and re-
lated compounds exist in nature and all 
of them must be distinguished and quan-
tified in order to make a connection be-
tween them and cancer. For the past 
several years. Dr. Groopman and his col-
leagues have concentrated on developing 
an accurate, high-speed screening test for 
the presence of aflatoxin in any sample, 
including grains, milk and urine. Their 
efforts led to the development in 1986 of 
the Aflatest Mycotoxin Testing System, 
which has been described by Dr. Groop-
man as a "revolutionary advance" in the 
field. 
' 'Aflatest is a one-step purification pro-
cedure that can detect and measure 
continued on page 2 
Special Center 
Facility Provides 
Essential Services for 
Cancer Researchers 
Successful research at the Hubert H. 
Humphrey Cancer Research Center 
depends not only on the inventiveness of 
its investigators but also on essential sup-
port laboratories, such as the Hybridoma 
Facility, which provide equipment and 
technical expertise that an individual 
laboratory may not have. 
The Hybridoma Facility of the Cancer 
Center has been in operation since the 
Center opened five years ago, and is 
available to all Center investigators and 
other researchers at Boston University 
Medical Center who are interested in 
producing monoclonal antibodies for 
their research projects. 
"Our people depend on the Facility to 
support their research. These kinds of 
specialized laboratories are expensive 
but absolutely essential to our work," 
says Herbert Wotiz, Ph.D., director of 
the Center. Dr. Wotiz' own group, one 
of several that currently has projects 
under way at the Facility, is developing 
monoclonal antibodies for hormone re-
search. 
The Facility is directed by Ann 
Marshak-Rothstein, Ph.D., an assistant 
professor of microbiology and public 
health (environmental health), and is 
staffed by Rachel Ettinger, senior 
laboratory technician. It is Ms. Ettinger 
who consults directly with the client 
laboratories to design the protocols for 
developing the antibody of choice. Each 
laboratory using the Facility is respon-
continued on page 3 
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Research on Aflatoxin 
continued from page 1 
minute amounts of aflatoxin in five 
minutes in the field instead of two days 
in the laboratory, which was the case 
with the previous existing methods," 
says Dr. Groopman, who also is an as-
sociate professor of public health (en-
vironmental health) and an assistant 
professor of microbiology at the School 
of Medicine. (Aflatest is patented and 
being manufactured by a Medford, 
Mass., firm.) 
Like so much current research on can-
cer diagnosis and treatment, the Aflatest 
approach utilizes monoclonal antibodies, 
which were developed in the Hybridoma 
Facility of the Cancer Center (see related 
story). Dr. Groopman and his colleagues 
were able to develop various monoclonal 
antibodies—molecular probes that tight-
ly bind to a specific target chemical—for 
different aflatoxins. "Aflatest relies on 
the direct measurement of the inherent 
physical properties of the aflatoxin 
molecule, not on an indirect measure as 
in other tests," explains Dr. Groopman. 
Dr. Groopman has been testing the new 
procedure over the last four years in 
epidemiologically designed studies of 
aflatoxin exposure in areas of China and 
Africa in an attempt to link the toxin to 
liver cancer incidence. He is hoping that 
the procedure soon can be implemented 
in this country to test milk supplies at the 
individual farm level, before they are 
mixed at collection centers. 
A chemoprotective agent? 
Using Aflatest to further his studies on 
aflatoxin. Dr. Groopman now is working 
on ways to intervene with a variety of 
chemical compounds to ameliorate the ef-
fects of aflatoxin exposure. He believes 
that aflatoxin may cause cancer by 
damaging the DNA of cells, which then 
leads to tumors. Sulfur-containing com-
pounds known as antioxidants may 
prevent this genetic disruption in the first 
place and thereby protect against the 
harmful effects of aflatoxin exposure. 
Experiments with rats given a variety of 
antioxidants such as ethoxyquin showed 
a much lower incidence of tumors after 
aflatoxin exposure. 
The biochemical explanation of this 
observation, according to Dr. Groopman, 
is that the antioxidant causes an increase 
in the level of a particular enzyme impor-
tant in ridding the body of many toxic 
substances, including aflatoxins. If the 
antioxidant is removed, the enzyme level 
drops again. In addition, in controlled ex-
periments there was a 95-percent reduc-
tion in the incidence of original DNA 
mutations in animals that were treated 
with the antioxidant before exposure to 
aflatoxin. And if there is less DNA 
damage to begin with, there will be 
fewer tumors, says Dr. Groopman. 
Ethoxyquin, and certain other commer-
cial antioxidants often used in packaged 
foods to preserve freshness, are highly 
toxic in large doses and are, therefore, 
impractical to use as therapeutic agents. 
Instead, Dr. Groopman is concentrating 
on a synthetic compound known as ol-
tipraz, which has shown some promise. 
"Because its toxicity is so much less 
than other antioxidants and because it 
also suppresses initial DNA adduct for-
mation (mutation) we have high hopes 
for it as a chemoprotective agent against 
aflatoxin exposure," said Dr. Groopman 
at a recent meeting of industry execu-
tives held at the School of Medicine. 
Dr. Groopman believes in the impor-
tance of trying to develop drugs that 
have chemoprotective qualities, which 
could have major applications in 
animals. For example, in developing 
countries cows that have to eat grains 
contaminated with aflatoxin could be 
protected from those contaminants; if the 
cows don't get sick, not only does milk 
production increase but the milk supplies 
are rid of contaminants as well. 
However, much more work is necessary 
before such therapies can be put into ef-
fect. 
ACR Treasurer Carol 
Epstein, left, ACR mem-
ber Janet Libin, center, 
and ACR President 
Roberta Shlager recent-
ly presented Center re-
searchers Richard 
Miller, M.D.,Ph.D., 
second left, and Thomas 
Rothstein,M.D.,Ph.D., 
with equipment for lym-
phocyte research. 
(Photo by Lucy Milne, 
Educational Media, 
BUSM) 
Aid for Cancer Research Embarks on 40th Year The Fall of 1987 marks Aid for Cancer 
Research's 40th year of raising funds to 
help support cancer research in the 
greater Boston area. This small, non-
profit, totally volunteer and completely 
independent group of 28 women has 
raised more than $1.5 million for cancer 
research over the last 39 years. 
Aid for Cancer Research was one of 
the first donors to the Humphrey Center 
and their seed money, provided to the 
Center when it first opened, has been fol-
lowed by gifts every year since. Their 
primary fundraising activities are an an-
nual luncheon and fashion show (at-
tended by 1,200 to 1,500 people) and an 
ongoing memorial and other-occasion 
fund. All monies raised by the group are 
distributed with the counsel of a volun-
teer medical advisory board. 
The group's gifts include one or two 
yearly research fellowships, equipment 
and outright funds, according to ACR 
spokeswoman Elaine Klubok. In 1986, 
ACR gave the Humphrey Center more 
than $12,500 to purchase needed equip-
ment. In 1987, several researchers have 
benefited from the group's efforts. 
A sample of what ACR funds have 
provided the Center include a Zeiss 
micromanipulator and microinjector and 
a Narashige micropipette puller for 
Judith Campisi, Ph.D., an assistant 
professor of biochemistry, to facilitate 
her work on oncogenes. Funds also were 
given to Richard Niles, Ph.D., a profes-
sor of biochemistry and surgery, and 
Stephen Farmer, Ph.D., an associate 
professor of biochemistry, for a laser-
scanning densitometer to analyze and 
compare DNA and RNA sequences from 
normal and cancer cells; for a bac-
teriological shaker to grow bacterial cul-
tures that contain recombinant DNA that 
are used in the above analyses; and most 
recently, for a Zeiss tissue culture micro-
scope with a special optical device that 
continued on page 3 
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Rachel Ettinger, senior laboratory technician, at work in the Hybridoma Facility of the 
Humphrey Cancer Center. (Photo by Domenic Screnci, Educational Media, BUSM) 
Special Center Facility 
continued from page 1 
sible for immunizing mice with the par-
ticular antigen they are interested in and 
for developing a screening procedure to 
test whether antibodies have been raised 
against this particular agent. All tissue-
culture procedures involved in the 
production of monoclonal antibodies are 
then carried out by Ms. Ettinger. 
The procedure sounds straightforward: 
Eirst, researchers immunize a mouse by 
injection with a particular agent. The 
mouse then begins to produce antibodies 
to that antigen. When enough of a 
response has been observed, cells from 
the spleen are mixed with a myeloma 
cell line in culture to form hybridomas. 
Some of these hybridomas will produce 
the desired antibody in perpetuity. The 
best antibody for the particular antigen is 
selected and cloned to produce the raw 
material for the investigator's experi-
ment. 
"Sometimes an antigen is very im-
munogenic, that is, you get a response 
from the mouse in just a couple of 
months. You can then go ahead and fuse 
the antibody cells with a tumor cell line 
and grow the clones for another two 
months and then you're ready to do 
whatever experiment the investigator 
wanted," explains Ms. Ettinger. "Some-
times, though, the animals don't respond 
to the antigen for six months to a year, or 
maybe never. All you can do is try a dif-
ferent animal species or protein carrier.'' 
Ms. Ettinger is adept at dealing with 
setbacks of this sort and often employs a 
variety of biomolecular tricks to obtain 
the desired antibody. One of the most 
successful tasks she has had so far was in 
helping to produce monoclonal an-
tibodies for research on chemical car-
cinogenicity being conducted by John 
Groopman, Ph.D. (see related story). In 
this project, antibodies to many forms of 
aflatoxin were produced and the result 
has been a highly successful new test for 
the presence of this dangerous con-
taminant. And recently, Ms. Ettinger has 
carried out work for Cancer Center mem-
ber Paul Pilch, Ph.D., an associate profes-
sor of biochemistry at the School of 
Medicine, to produce antibodies that can 
recognize cell vesicles that have been 
stimulated by insulin as opposed to non-
stimulated ones. 
The usefulness of the Hybridoma 
Facility to the work of the Cancer Center 
can be seen in the steadily growing num-
ber of projects that are awaiting Ms. 
Ettinger's attention. Typically she has as 
many as five procedures going at any 
one time, all at different stages of 
progress. 
"Without such a facility," remarks 
Dr. Wotiz, "it would be much more dif-
ficult to get on with a lot of our work 
here." 
Aid for Cancer 
continued from page 2 
allows cells to be viewed in three dimen-
sions rather than just flat sections. In ad-
dition, the group purchased a BioGuard 
Laminar Flow Hood for Se-Kyung Oh, 
Ph.D., an assistant professor of 
microbiology. 
"We cannot underestimate the impor-
tance of this sort of volunteer effort," 
says Center Director Herbert Wotiz, 
Ph.D. "Aid for Cancer Research's con-
sistent support of our work means a great 
deal to us and the fight against cancer, 
and we are very grateful.'' 
Aid for Cancer Research has an-
nounced a new two-year fellowship avail-
able for cancer investigators. The fellow-
ship, to be awarded in the spring of 1988, 
will be for $22,000 to $22,500, accord-
ing to ACR. Deadline for applications is 
Dec. 31. For information, write to 
ACR at 25 Liberty Street, Natick, MA, 
01760. 
QUESTIONS... 
Answer to question on back panel. 
i ^ . . The good news is that some cancers, 
which only a few decades ago had a very 
poor outlook, today are being cured: acute 
lymphocyt ic leukemia in chi ldren, 
Hodgkin's disease, Burkitt's lymphoma, 
Ewing's sarcoma (a form of bone cancer), 
W i l m s ' tumor (a kidney cancer in 
children), rhabdomyosarcoma (a cancer in 
certain muscle tissue), choriocarcinoma 
(placental cancer), testicular cancer, 
ovarian cancer and osteogenic sarcoma. 
Other cancers, however, have not yet 
yielded to effective treatment and are the 
focus of continuing research. 
The diagnosis and treatment of cancer 
has become increasingly individualized. 
Early detection is followed by a more 
precise description of stages and the use 
of more than one kind of therapy, often 
in combination. An outstanding example 
of progress is the improvement in the 
management of testicular cancer in 
young men. More precise diagnostic 
tools and staging allow a better selection 
of treatment. The use of combinations of 
cancer drugs has resulted in remarkably 
improved survival. In 20 years, the five-
year survival rate of testicular cancer 
rose from 63 percent to 88 percent. 
Can Cancer be prevented? 
JAL. Some cancers can be prevented but 
not all. Most lung cancers are caused by 
cigarette smoking and most skin cancers by 
frequent over-exposure to direct sunlight. 
These cancers can be prevented by avoid-
ing their causes. Certain cancers caused by 
occupational-environmental factors can be 
prevented by eliminating or reducing con-
tact with carcinogenic agents. 
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CANCER NOTES 
CANCER NOTE: Research has shown 
there is no such thing as a "safe" 
cigarette, but that those who are not yet 
able to quit are well advised to switch to 
brands with the lowest possible tar and 
nicotine content. Moreover, low T/N 
smokers find it easier to quit altogether 
than high T/N smokers. Remember that 
in addition to harmful tar and nicotine, 
cigarette smoke contains a number of 
poisonous gases such as hydrogen 
cyanide and carbon monoxide—^possibly 
a critical factor in coronary heart disease 
and fetal growth retardation. 
CANCER NOTE: The incidence of 
uterine cancer in 1987 was estimated to 
be 48,000 new cases, including 13,000 
cases of cervical cancer and 35,000 cases 
of endometrial cancer, or cancer of the 
uterus. Overall, the death rate from 
uterine cancer has decreased 70 percent 
during the last 40 years, due mainly to 
Pap tests and regular checkups. 
CANCER NOTE: Oral cancer can 
affect any part of the oral cavity from lip 
and tongue to mouth and throat. In-
cidence is more than twice as high in 
men as in women, and is most frequent 
in men over age 40. Cigarette, cigar and 
pipe smoking, use of smokeless tobacco. 
and excess use of alcohol are all risk fac-
tors for the disease. 
The Humphrey Cancer Center News is 
published for the Hubert H. Humphrey 
Cancer Research Center of Boston 
University School of Medicine by the 
Office of Publication Services, Boston 
University Medical Center. Humphrey 
Center Director, Herbert H. Wotiz, 
Ph.D.; Editor, William T. Harris; Writer, 
Caroline H. Lupfer. ''Cancer Notes' ' 
information is provided courtesy of the 
American Cancer Society. 
What is the good news 
about cancer today? 
ANSWER ON PAGE 3 
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